Menu
Not yet recruiting NCT07637760

Dry Needling or Percutaneous Electrolysis for Managing Myofascial Trigger Points?

No phase Interventional Shoulder Pain

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Dry needling, Percutaneous electrolysis, Manual therapy, Therapeutic exercise.
Who it may be relevant to
Registry conditions: Shoulder Pain. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Spain
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Dry Needling or Percutaneous Electrolysis for Managing Myofascial Trigger Points? A Randomized Clinical Trial

Overview

Dry needling (DN) and percutaneous electrolysis (PE) are minimally invasive physiotherapy techniques commonly used for the management of myofascial trigger points. DN consists of inserting a fine filiform needle into a hyperirritable area within a taut band of skeletal muscle, with the aim of eliciting local twitch responses and reducing myofascial pain. PE follows a similar needle-based approach but combines the mechanical stimulus of the needle with the application of a galvanic electrical current, producing an electrochemical reaction in the targeted tissue. Both techniques have been increasingly used in clinical practice for musculoskeletal pain conditions, including shoulder pain, although the evidence comparing their relative effectiveness remains limited. Shoulder pain is one of the most prevalent musculoskeletal disorders and is frequently associated with the presence of active myofascial trigger points. Among the shoulder muscles, the infraspinatus has been identified as a clinically relevant structure because its trigger points may reproduce referred pain patterns commonly reported by patients with shoulder symptoms and may contribute to pain, reduced strength, altered mobility, and functional disability. Previous studies have suggested that invasive treatment of infraspinatus trigger points may produce short-term improvements in pain sensitivity and shoulder-related symptoms. However, most available research has examined dry needling or percutaneous electrolysis separately, and direct comparisons between both interventions in patients with shoulder pain remain scarce. The physiological mechanisms underlying these techniques are not yet fully understood. Dry needling is thought to act through mechanical and neurophysiological mechanisms, including disruption of dysfunctional motor endplates, reduction of local nociceptive input, elicitation of local twitch responses, and activation of segmental and descending inhibitory pathways. Percutaneous electrolysis may share some of these needling-related effects, while also adding a galvanic current that may induce local biochemical changes and promote tissue recovery processes. Nevertheless, it remains unclear whether the addition of electrical current provides superior clinical effects compared with dry needling alone. Since limited research has directly compared dry needling and percutaneous electrolysis applied to active myofascial trigger points of the infraspinatus in patients with shoulder pain, the present study aimed to compare the effectiveness of both techniques as complementary interventions to manual therapy and therapeutic exercise. Specifically, this study sought to determine whether percutaneous electrolysis or dry needling produced greater short-term improvements in pain intensity and shoulder-related disability.

Interventions

  • Other Dry needling
    Dry needling will be performed on the most symptomatic active myofascial trigger point of the infraspinatus muscle. Participants will be placed in prone, and the skin will be disinfected with 2% chlorhexidine. A sterile solid filiform needle will be inserted into the trigger point using Hong's technique, consisting of repeated fast-in and fast-out needle movements for 30 seconds, with the aim of eliciting 3-5 local twitch responses. During the 30 seconds procedure, the needle will be connected t
  • Other Percutaneous electrolysis
    Percutaneous electrolysis will be applied to the most symptomatic active myofascial trigger point of the infraspinatus muscle. Participants will be positioned in prone, and the skin will be cleaned with 2% chlorhexidine. A sterile solid filiform needle will be inserted into the trigger point using a fast-in and fast-out needling approach, with the aim of eliciting 3-5 local twitch responses. During the procedure, a galvanic current of 0.3 mA was applied for 30 seconds.
  • Other Manual therapy
    Manual therapy interventions consist of soft tissue techniques targeting the upper, middle, and lower trapezius, levator scapulae, rhomboids, teres minor, and infraspinatus muscles. The pressure will be adapted to each participant's tolerance and will not exceed moderate pain intensity. Scapular mobilization techniques will be also performed in side-lying, including elevation, depression, protraction, retraction, upward rotation, and downward rotation.
  • Behavioral Therapeutic exercise
    The programme include assisted mobility exercises for shoulder flexion, abduction, external rotation, and internal rotation, followed by strengthening exercises for flexion, extension, abduction, internal rotation, and external rotation. Anterior and posterior shoulder capsule stretching and unloaded Codman pendulum exercises will be also included. Participants will be instructed to perform the exercises once daily until the follow-up assessment, keeping pain below 3-4 points on the visual analo

Primary outcome measures

  • Pain intensity [Time frame: Baseline (before the intervention on Day 1) and 7 days after the intervention]
Secondary outcome measures (3)
  • Shoulder disability [Time frame: Baseline (before the intervention on Day 1) and 7 days after the intervention]
  • Adverse effects [Time frame: From completion of the intervention on Day 1 to 7 days after the intervention]
  • Interventions tolerance [Time frame: Immediately after completion of the intervention on Day 1]

Eligibility criteria

Inclusion criteria

  • Adults
  • Presence of shoulder pain for at least 3 months.
  • Shoulder pain intensity greater than 3 points on the visual analogue scale (VAS).
  • Shoulder-related disability greater than 20 points on the DASH questionnaire.
  • Presence of at least one active myofascial trigger point in the infraspinatus muscle.
  • Reproduction of the patient's familiar shoulder pain during palpation of the infraspinatus trigger point.
  • Ability to understand the study procedures and provide written informed consent.

Exclusion criteria

  • Previous shoulder surgery or traumatic shoulder injury in the affected region.
  • Presence of severe structural or systemic pathology affecting the shoulder region, such as fracture, tumour, infection, inflammatory disease, or neurological disorder.
  • Clinical signs suggestive of cervical radiculopathy or other neurological conditions that could explain the shoulder symptoms.
  • Use of physiotherapy treatment, invasive therapy, or analgesic/anti-inflammatory medication during the week before participation.
  • Contraindications to dry needling or percutaneous electrolysis, including needle phobia, anticoagulant therapy, bleeding disorders, pregnancy, pacemaker or implanted electrical devices, local skin infection, or altered skin sensitivity in the treatment area.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Quadruple blind
Primary purpose
Treatment

Study locations

Spain · 1 center
  • Complutense University of Madrid — Madrid

Identifiers

NCT: NCT07637760 · PEDN

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗